Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics (TNGX) reported Phase 1/2 results for vopimetostat combinations with RAS(ON) inhibitors. As of August 20, 2026, the daraxonrasib combination had an 82% objective response rate and an 88% nine-month progression-free survival rate among 22 efficacy-evaluable patients with second- or third-line MTAP-deleted, RAS-mutant pancreatic cancer; median PFS was not reached. Dose level 1 was generally well-tolerated, while dose level 2 had 3 dose-limiting toxicities in 2 patients. The NSCLC cohort had an 80% ORR in 4 of 5 patients.
For vopimetostat plus zoldonrasib, 35 efficacy-evaluable PDAC patients had a 54% ORR, a 61% nine-month PFS rate and a 97% disease control rate. Tango plans a global randomized Phase 3 trial of vopimetostat plus daraxonrasib in first-line MTAP-deleted PDAC in the first half of 2027. The company is reprioritizing research toward PRMT5 programs, deprioritizing novel target discovery, and intends to reduce its workforce by approximately 14%, mostly in research. Cash and investments were $1.0 billion as of June 30, 2026.
At Tango Therapeutics, Inc. (TNGX), President, R&D Adam Crystal exercised options for 27,000 shares of common stock at an exercise price of $5.20 per share on October 1, 2026, and reported 233,040 stock options following the transaction. He also sold 26,400 shares at a weighted average of $24.4547 per share and 600 shares at a weighted average of $25.32 per share. The transactions were made under a Rule 10b5-1 trading plan adopted October 27, 2025.
Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb sold 8,200 shares of common stock on September 22, 2026, in three transactions: 700 shares at a weighted-average $22.8029 per share, 5,100 at $23.9683, and 2,400 at $25.1718. The sales were made under a Rule 10b5-1 trading plan adopted June 23, 2026. The reported amount owned following the transactions included 43,666 unvested RSUs, each a contingent right to receive one common share.
Tango Therapeutics, Inc. (TNGX) has an affiliate officer, Jessica Newcomb, filing a notice to sell common stock under Rule 144. The filing covers up to 15,231 shares of Tango Therapeutics common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $340,108.23 as of September 22, 2026.
The shares include 10,236 shares acquired upon vesting of Employee Stock Purchase Plan shares during the period from April 30, 2024 through April 30, 2025, and 4,995 shares acquired upon vesting of restricted stock units during the period from February 5, 2024 through February 3, 2025. Tango Therapeutics reports 168,610,367 shares of common stock outstanding, providing context for the size of this planned sale.
Tango Therapeutics, Inc. (TNGX) reported that Crystal Adam, President, R&D, exercised stock options for 27,000 shares of common stock on September 1, 2026 at an exercise price of $5.20 per share and sold 27,000 shares at a weighted average price of $22.367 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Following the option exercise, Adam held 260,040 stock options directly, which remain outstanding and exercisable through their stated expiration, subject to the vesting schedule.
Tango Therapeutics, Inc. received an amended Schedule 13G filing in which Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo report that they beneficially own 0 shares of Tango Therapeutics common stock.
As of June 30, 2026, each reporting person discloses 0.0% of the class, with no sole or shared voting or dispositive power. They also indicate that they now hold 5 percent or less of Tango Therapeutics’ common stock.
TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu report beneficial ownership of Tango Therapeutics, Inc. Common Stock. Each reporting person is deemed to beneficially own 10,147,867 shares, representing 7.0% of the class, including 9,081,201 shares of Common Stock and 1,066,666 shares underlying Pre-Funded Warrants exercisable within 60 days. The Pre-Funded Warrants are subject to a 9.99% Beneficial Ownership Limitation, and the reporting persons state that they collectively hold less than this threshold. The percentage is calculated based on 145,714,648 shares of Common Stock, consisting of 144,647,982 shares outstanding as of May 6, 2026 plus the warrant shares assumed exercisable. The reporting persons disclaim group status and beneficial ownership beyond their pecuniary interests.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of common stock of Tango Therapeutics, Inc. on a Schedule 13G. The holding represents 6.0% of Tango’s common stock.
The filing shows shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares, with an aggregate beneficial ownership of 9,742,402.80 shares. The securities are attributed to Goldman Sachs & Co. LLC as a broker-dealer and investment adviser subsidiary of The Goldman Sachs Group, Inc., which is reporting as a parent holding company. The Goldman Sachs reporting units disclaim beneficial ownership of certain client accounts and investment entities as described in the disclosure.
Woodline Partners LP filed an amended Schedule 13G reporting its position in Tango Therapeutics, Inc. common stock. Woodline Partners, a Delaware limited partnership and investment adviser to two master funds, reports beneficial ownership of 4,000,567 shares of Tango common stock, with sole voting and dispositive power over all of these shares and no shared power. Based on an aggregate of 162,814,649 shares of Tango common stock outstanding, Woodline’s holdings represent approximately 2.5% of the class. The outstanding share figure reflects 18,166,667 shares offered under a June 10, 2026 prospectus plus 144,647,982 shares outstanding as of May 6, 2026.
Farallon Capital Management, L.L.C. and affiliated funds report beneficial ownership of Tango Therapeutics, Inc. common stock. The Farallon Funds together hold 12,277,000 Shares and 3,993,187 Pre-Funded Common Stock Purchase Warrants, each warrant exercisable for one Share, subject to a 9.99% Beneficial Ownership Limitation. Assuming all warrants are exercisable within 60 days, the Reporting Persons disclose beneficial ownership of 16,270,187 Shares, representing 9.8% of Tango’s outstanding common stock. Farallon Capital Management acts as investment manager to the Farallon Funds, and multiple individual managing members share voting and dispositive power over these securities.